Shi Yuanyuan, chairman of Shenzhen Cell Valley, was invited to participate in the "Meet Pingshan · Foresee the future" industrial chain innovation salon
On April 27, Shi Yuanyuan, chairman of our company, was invited to participate in the fifth phase of the industrial chain innovation Salon of "Meeting Pingshan · Foreseeing the Future" sponsored by the Organization Department of Pingshan District Committee and hosted by Pingshan District High-level Talent Association. Also present at the event was Dr. Xiao Ping, Director of Peking University Clinical Research Institute (Shenzhen) and former Vice President of Peking University Shenzhen Hospital. Dr. Wang Mingjun, CEO of Shenzhen Innuo Immunization Co., LTD., Li Hongjian, chairman of Shenzhen Puruijin Biopharmaceutical Co., LTD., and more than 30 representatives of experts and investors from Guangdong-Hong Kong-Macao Greater Bay Area, and the Organization Department of Pingshan District Party Committee, Pingshan District Science and Technology Innovation Service Center and other departments in charge.
This salon focused on the issues related to the three leading industries in Pingshan, with the topic of "Development and future of cell and gene therapy industry" as the topic, exchanged the most cutting-edge development strategies, sorted out the core issues of the whole chain of cell and gene therapy industry and proposed corresponding solutions, and promoted the cooperation and linkage between the industrial chain in Pingshan District.
Shi Yuanyuan, chairman of our company, said that the next decade will be the most rapidly changing decade in China's pharmaceutical field, and China will fully complete the comprehensive reconstruction of the pharmaceutical industry chain, and platform construction is the top priority. At present, the cell industry is still in its own battle, more but not strong stage, pharmaceutical companies from research and development to production cycle is long, human and resources, lack of funds, and clinical and regulatory communication bridge is not smooth, so it is necessary to build a stronger one-stop outsourcing service platform to help pharmaceutical companies solve the above problems, in order to continue to add momentum for the biomedical industry.
